Stock 4563 ANGES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases AnGes, Inc.

Equities

4563

JP3127700007

Delayed Japan Exchange
Other stock markets
 05:56:38 10/05/2024 am IST 		5-day change 1st Jan Change
50 JPY 0.00% Intraday chart for AnGes, Inc. +2.04% -30.56%
19/01 Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease MT
18/01 Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AnGes : Notice Regarding the Decision to Sell the ZOKINVY Business of Eiger BioPharmaceuticals, Inc.
PU
AnGes : Notice on the NHI Drug Price Standard Listing and Launch Schedule of Zokinvy for the Treatment of Progeria
PU
AnGes : Notice Regarding Eiger BioPharmaceuticals, Inc.
PU
AnGes : Notice of Business Restructuring at Consolidated Subsidiary
PU
AnGes : Notice of Conclusion of License Agreement and Revision of Consolidated Financial Results Forecast for FY2024
PU
Eiger and Partner, AnGes, Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
AQ
AnGes : Consolidated Financial Report for the Third Quater 2023
PU
AnGes : Notice Regarding the Start of Administration of NF-κB Decoy Oligo DNA for the Treatment of Chronic Intervertebral Disc Lumbago in a Phase II Clinical Trial in Japan
PU
AnGes : Consolidated Financial Report Q2 2023
PU
AnGes : Consolidated Financial Report for the Second Quater 2023
PU
AnGes : Clinical Research Laboratory has now established "Genetic Testing" technology and aims to begin accepting orders for "genetic testing" in winter 2023
PU
AnGes : Begin contracted expanded newborn screening from municipalities and related institutions from April 2024 at AnGes Clinical Research Laboratory
PU
AnGes : Begin contracted expanded newborn screening from municipalities and related institutions from April 2024 on AnGes Clinical Research Laboratory
PU
AnGes : filed for approval of its HGF gene therapy product Collategene® for the first time since the introduction of the conditional/time-limited authorization system for regenerative medicine products
PU
AnGes : Notice on the Filing of an Application for Manufacturing and Marketing Approval of Zokinvy for the Treatment of Premature Aging Syndrome
PU
AnGes : Consolidated Financial Report for the First Quater 2023
PU
AnGes : Notice Concerning Acquisition and Cancellation of the 42nd Series of Stock Acquisition Rights
PU
Notice of Orphan Drug Designation for lonafarnib (U.S. brand name: Zokinvy) for the treatment of premature aging (HGPS and PL)
PU
AnGes : Notice of Completion of Patient Enrollment in Late Phase II Clinical Trial of HGF Gene Therapy Product "Collategene" in the U.S.
PU
AnGes : Notice of Reduction of Capital Stock and Capital Reserve and Appropriation of Surplus
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4563 Stock
  4. News AnGes, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW